Investors

Vicore Pharma Holdings share is listed on NASDAQ First North since December 10, 2015

Share information
  • Ticker symbol for First North: VICO
  • ISIN-code: SE0007577895
  • The shares are registrered by securities depository, Euroclear Sweden AB.

Important information about Nasdaq Stockholm First North

Companies whose shares are traded on First North are not required to follow the same rules as companies whose shares are traded on the regulated main market; instead they use a less extensive rulebook than the main market, which is adapted for smaller growth companies.An investment in a company whose shares are traded on First North may therefore carry more risk than an investment in a company whose shares are traded on a regulated market. All companies whose shares are traded on First North have a Certified Adviser to ensure they comply with all requirements and rules for disclosure of information to the market and investors. A Certified Adviser monitors the company whose shares will be listed for trading on First North, and NASDAQ approves such an application for listing.

Development of share capital

YearEventQuota valueIncrease in number of sharesIncrease in share capitalTotalt number of sharesTotal share capital
2005Formation1001 000100 000,001 000100 000,00
2008Bonus issue1004 601460 100,005 601560 100,00
2008Breakdown of shares 1:20000,0511 196 399-11 202 000560 100,00
2008Share issue0,0568834,411 202 688560 134,40
2010Share issue0,055 601 344280 067,2016 804 032840 201,60
2010Share issue0,055 601 344280 067,2022 405 3761 120 268,80
2010Set-off issue0,051 000 00050 000,0023 405 3761 170 268,80
2011Share issue0,0510 402 389520 119,4533 807 7651 690 388,25
2012Set-off issue0,05474 49823 724,9034 282 2631 714 113,15
2013Share issue0,0534 282 2631 714 113,1568 564 5263 428 226,30
2015Share issue0,0512 639 073631 953.6581 203 5994 060 179,95
2015reversed split 1:100,5-73 083 239-8 120 3604 060 180,00
2015Share issue/Listing0,53 248 1441 624 07212 368 5045 684 252,00
2017Share issue0,52 000 0001 000 00014 368 5047 184 251,92
2017Share issue0,51 500 000750 00015 868 5047 934 251,92

Shareholders

September 30, 2017

ShareholderNr of shares%
Total nr of shares
15 868 504
100%
Protem Wessman inkl. privat
2 348 382
14,8%
Swedbank Robur
1 570 000
9,9%
HBM Healthcare Investments (Cayman) Ltd
1 200 000
7,6%
Kjell Stenberg
1 148 478
7,2%
Pomona-gruppen AB
805 830
5,1%
Eriksam Invest AB inkl. privat
600 010
3,8%
Unionen
600 000
3,8%
AFA Försäkring
585 000
3,7%
Mikael Lönn
448 859
2,8%
BD Medical consulting AB
340 000
2,1%
Other
6 221 945
39,2%

Financial

Calendar

Year-end report 2017

February 21 2018

Annual report 2017

April 12 2018

Financial report, Q1

May 8 2018

Events &

Presentations

w

Biotech and Money Investival showcase
London, November 14, 2017

Jefferies Healthcare conference
London, November 15-16, 2017

Bolagsdagen (Company presentations), Erik Penser bank
Stockholm, November 23 2017

Stora aktiedagen (Swedish shareholders meet)
Göteborg, November 27, 2017

Audiocast/Conference call
Presentation of results from extension study
October 2, 2017 at 14:00 CET

 

Previous events & presentations

BIO International Convention
San Diego, June 19-20, 2017

Jefferies Health Care Conference
New York, June 6-9, 2017

Per Jansson, CEO presents Vicore Pharma on event with Redeye on May 4, 2017
Early-bird company presentation, may 4, 2017

Interview with Per Jansson, CEO at Vicore Pharma:
CEO interview, april 10, 2017

Per Jansson, CEO presents Vicore Pharma on Stora aktiedagen in Gothenburg on november 14, 2016:

Company presentation november 14

Per Jansson, CEO presents Vicore Pharma on event with Aktiespararna in Stockholm on March 8, 2016:
Company presentation march 8, 2016

Per Jansson, CEO presents Vicore Pharma on Stora aktiedagen in Gothenburg on November 23 2015:
Company presentation November 23>>

Björn Dahlöf, Senior Medical Advisor presents Vicore Pharma on event with Redeye in Gothenburg on November 3, 2015:
Company presentation November 3>>

Per Jansson, CEO presents Vicore Pharma on event with Aktiespararna in Stockholm on october 19, 2015:
Company presentation October 19>>

Dawid Myslinski, Corporate Finance on Redeye talks about Vicore Pharma:
Dawid Myslinski on Vicore Pharma

Financial asset

Vicore Pharma Holding owns 16,5% of the shares in I-Tech AB.

I-Tech AB has developed and commercialized a marine biocide, Selektope, for use in antifouling paints. Selektope prohibits growth of barnacles on ship hulls.

Selektope holds the necessary regulatory approvals required for the use of the substance in the EU, China, Korea and Japan. In 2016, one of the largest paint manufacturer launched antifouling paints containing Selektope.

The largest shareholders in I-Tech are; Volvo Group Venture Capital, Vicore Pharma Holding, ALMI and Pomonagruppen.

Read more about I-Tech: www.selektope.com

Article of association

Read the article of association here!

Incentive programme

A total of 570,000 warrants were acquired by key employees and advisers in 2016. Each warrant entitles the holder to subscribe for one new share in Vicore Pharma Holding AB. Subscription for shares in accordance with the terms of the warrants may take place during the period up until December 8, 2019 (380 000 warrants) respectively January 3, 2020 (190 000 warrants).

 

If you have any questions as an investor, please contact us!

Per Jansson, CEO 
per.jansson@vicorepharma.com
M: +46 709 17 47 46

Nina Carlén, IR, Communicaton and Administration coordinator
nina.carlen@vicorepharma.com
M: +46 763 90 94 04

Certified Advisor
Erik Penser Bank AB
Apelbergsgatan 27
Box 7405
103 91 Stockholm, Sweden
T: +46 8 463 8000